PhAST Diagnostics

PhAST Diagnostics is a private, pre-revenue company founded in 2019 that is developing an AI-powered diagnostic platform to address the global crisis of antimicrobial resistance (AMR). Its core technology combines single-cell imaging, microfluidics, and machine learning to rapidly identify pathogens and their antibiotic susceptibility, aiming to reduce diagnostic timelines from days to minutes. The company targets a three-pronged business model serving clinicians, hospitals, and pharma R&D, positioning itself at the intersection of AI diagnostics and infectious disease management. With a strong, multidisciplinary team and esteemed scientific advisors, PhAST is building a platform with significant potential impact on both clinical outcomes and public health.

AI/ML-powered cloud platform combining single-cell imaging, microfluidics, and computer vision for rapid pathogen identification and antibiotic susceptibility testing.

PhAST competes with large diagnostics companies (e.g., bioMérieux, Becton Dickinson, Danaher) developing rapid AST solutions, as well as other AI-driven microbiology startups (e.g., Specific Diagnostics, Day Zero Diagnostics). Its differentiation lies in the single-cell imaging phenotype-based approach and a fully integrated cloud-AI platform.